120 related articles for article (PubMed ID: 2935125)
1. Abnormal retinal function associated with fenretinide, a synthetic retinoid.
Kaiser-Kupfer MI; Peck GL; Caruso RC; Jaffe MJ; DiGiovanna JJ; Gross EG
Arch Ophthalmol; 1986 Jan; 104(1):69-70. PubMed ID: 2935125
[TBL] [Abstract][Full Text] [Related]
2. Effects of fenretinide (4-HPR) on dark adaptation.
Caruso RC; Zujewski J; Iwata F; Podgor MJ; Conley BA; Ayres LM; Kaiser-Kupfer MI
Arch Ophthalmol; 1998 Jun; 116(6):759-63. PubMed ID: 9639444
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of fenretinide on retinal function.
Decensi A; Fontana V; Fioretto M; Rondanina G; Torrisi R; Orengo MA; Costa A
Eur J Cancer; 1997 Jan; 33(1):80-4. PubMed ID: 9071904
[TBL] [Abstract][Full Text] [Related]
4. Total rod ERG suppression with high dose compassionate Fenretinide usage.
Marmor MF; Jain A; Moshfeghi D
Doc Ophthalmol; 2008 Nov; 117(3):257-61. PubMed ID: 18523815
[TBL] [Abstract][Full Text] [Related]
5. Fenretinide does not block visual pigment formation in the rat.
Crouch RK; Goletz P
J Ocul Pharmacol; 1988; 4(3):253-7. PubMed ID: 2974060
[TBL] [Abstract][Full Text] [Related]
6. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
7. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
8. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.
Decensi A; Torrisi R; Polizzi A; Gesi R; Brezzo V; Rolando M; Rondanina G; Orengo MA; Formelli F; Costa A
J Natl Cancer Inst; 1994 Jan; 86(2):105-10. PubMed ID: 8271292
[TBL] [Abstract][Full Text] [Related]
9. Abnormal retinal function associated with isotretinoin therapy for acne.
Weleber RG; Denman ST; Hanifin JM; Cunningham WJ
Arch Ophthalmol; 1986 Jun; 104(6):831-7. PubMed ID: 2940999
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
Invest New Drugs; 1990 Aug; 8(3):317-9. PubMed ID: 2148744
[TBL] [Abstract][Full Text] [Related]
12. Night blindness and the retinal mechanism of visual adaptation.
Ripps H
Ann R Coll Surg Engl; 1976 May; 58(3):222-32. PubMed ID: 1083707
[TBL] [Abstract][Full Text] [Related]
13. Photoreceptor recovery in retinoid-deprived rats after vitamin A replenishment.
Katz ML; Chen DM; Stientjes HJ; Stark WS
Exp Eye Res; 1993 Jun; 56(6):671-82. PubMed ID: 8595809
[TBL] [Abstract][Full Text] [Related]
14. The synthetic retinoid fenretinide does not affect circulating hormone concentrations.
Secreto G; Costa A; Recchiane C; Pizzichetta M; Ballerini P
Breast Cancer Res Treat; 1988 Dec; 12(3):315-6. PubMed ID: 2976280
[No Abstract] [Full Text] [Related]
15. Lack of correlation between plasmatic levels of retinol and RBP and thyroid hormones in breast cancer patients treated with the synthetic retinoid fenretinide.
Pizzichetta M; Formelli F; Bombardieri E; Bruni GF; Costa A
Int J Biol Markers; 1990; 5(4):208. PubMed ID: 2151235
[No Abstract] [Full Text] [Related]
16. Ocular toxic effects of fenretinide.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
J Natl Cancer Inst; 1990 Jun; 82(12):1063. PubMed ID: 2140863
[No Abstract] [Full Text] [Related]
17. Fenretinide and its relation to cancer.
Ulukaya E; Wood EJ
Cancer Treat Rev; 1999 Aug; 25(4):229-35. PubMed ID: 10448131
[TBL] [Abstract][Full Text] [Related]
18. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
[TBL] [Abstract][Full Text] [Related]
19. Delayed dark adaptation caused by nilutamide.
Chan P; Odel JG
J Neuroophthalmol; 2008 Jun; 28(2):158-9. PubMed ID: 18562852
[No Abstract] [Full Text] [Related]
20. Electroretinographic findings in subjects after administration of fenretinide.
Krzeminski R; Zwas F; Esper P; Pienta K
Doc Ophthalmol; 1995-1996; 91(4):299-309. PubMed ID: 8899300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
